- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3 - Justifying Costs: A Request for More Evidence
Payers are often hesitant to cover more expensive, newly approved therapies. Many want to base their formulary decisions on evidence, which in many cases is limited. Richard Joseph, MD, describes this as “a difficult dilemma,” adding that “Trying to get an evidence for each scenario is a really challenging thing.”
Collecting evidence can be costly and may not provide more insight into justifying a therapy’s use, and cost, than a provider’s expert opinion. Still, care and coverage are often dictated by an individual’s form of insurance. Ideally, as data on new therapies and their costs accumulate, coverage and reimbursement considerations will align more and more closely with the evidence
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
